2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
02/02/17First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
Second Clinical Candidate Generated by MyoKardia’s Product Engine Topline Results Expected in the Third Quarter of 2017              SOUTH SAN FRANCISCO, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced dose administration for the first cohort of healthy subjects in its Phase 1 single ascending dose study of MYK-... 
02/01/17MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of June Lee, M.D., as chief operating officer, and Radhika Tripuraneni, M.D., as vice president, medical affairs. "I am thrilled to welcome these two exceptional life sciences leaders to the MyoKardia team at this pivotal time as... 
01/03/17MyoKardia Announces Advancement to Next Phase of Global Collaboration with Sanofi
Sanofi Decision to Continue Provides $45 Million Milestone to MyoKardia Collaboration has Advanced Two Novel Clinical Compounds SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, announced today that Sanofi has notified the Company that it has elected to continue the global cardiomyopathy research collaboration...